<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082082</url>
  </required_header>
  <id_info>
    <org_study_id>Ta1-HCC-2K1001</org_study_id>
    <nct_id>NCT00082082</nct_id>
  </id_info>
  <brief_title>A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SciClone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SciClone Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this Phase II trial is to compare the efficacy and safety of 6 months of&#xD;
      treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in&#xD;
      adult patients with non-surgical hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymalfasin (thymosin alpha-1)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans arterial chemoembolization (TACE)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Diagnosis of HCC by:&#xD;
&#xD;
               1. Presence of HCC on biopsy (core biopsy), or, if biopsy is strongly&#xD;
                  contra-indicated due to safety or patient-related concerns, then the diagnosis of&#xD;
                  HCC can be determined by:&#xD;
&#xD;
               2. A new hepatic defect on imaging with an AFP &gt; 1000 ng/ml, or&#xD;
&#xD;
               3. A new hepatic defect on ultrasound or CT with an AFP &lt; 1000 ng/ml when one of the&#xD;
                  following is present:&#xD;
&#xD;
                    1. At least two additional imaging techniques show signs characteristic of HCC,&#xD;
                       or&#xD;
&#xD;
                    2. The new hepatic defect has doubled in diameter over time, or&#xD;
&#xD;
                    3. The AFP has progressively risen to &gt; 200 ng/ml and triples the mean&#xD;
                       baseline.&#xD;
&#xD;
          -  HCC must be unresectable and non-transplantable.&#xD;
&#xD;
          -  Hematocrit &gt; 30%, platelet count &gt;= 50,000 per microliter, WBC &gt; 2.0 x 109/L, and&#xD;
             polymorphonuclear white cell count &gt;= 1.0 x 109/L.&#xD;
&#xD;
          -  Adequate renal function as demonstrated by serum creatinine level &lt; 1.5 mg/dl.&#xD;
&#xD;
          -  If the patient is a woman, she is using a definitive method of birth control in&#xD;
             consultation with her physician, or is surgically sterile or post-menopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant chronic use of any drug known to be hepatotoxic, or of any&#xD;
             immunosuppressive drug (Use of oral contraceptives will not exclude an otherwise&#xD;
             eligible patient).&#xD;
&#xD;
          -  Presence of main portal vein thrombosis or hepatic artery malformation.&#xD;
&#xD;
          -  HCC amenable to treatment by surgical resection or hepatic transplantation.&#xD;
&#xD;
          -  HIV infection diagnosed by HIV seropositivity and confirmed by Western blot.&#xD;
&#xD;
          -  Concomitant or prior history of malignancy other than HCC within the last 10 years,&#xD;
             except for curatively treated skin cancer or surgically cured in situ carcinoma of the&#xD;
             cervix.&#xD;
&#xD;
          -  Active infectious process that is not of a self-limiting nature. TB and AIDS are&#xD;
             examples of infectious processes that are not of a self-limiting nature.&#xD;
&#xD;
          -  Pregnancy as documented by a urine pregnancy test. Women with reproductive potential&#xD;
             must agree to practice an adequate method of birth control for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Alcohol or intravenous drug abuse within the previous 1 year.&#xD;
&#xD;
          -  Previous treatment with thymalfasin.&#xD;
&#xD;
          -  Patients with known hypersensitivity to iodine.&#xD;
&#xD;
          -  Simultaneous participation in another investigational drug study, or participation in&#xD;
             any clinical trial involving investigational drugs within 30 days of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>April 28, 2004</study_first_submitted>
  <study_first_submitted_qc>April 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2004</study_first_posted>
  <last_update_submitted>January 8, 2008</last_update_submitted>
  <last_update_submitted_qc>January 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

